Sulbactam–Durlobactam: A Novel Antibiotic Combination for the Treatment of Acinetobacter baumannii–Calcoaceticus Complex (ABC) Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia [PDF]
Canadian Journal of Infectious Diseases and Medical MicrobiologySummary: Sulbactam–durlobactam is a recently approved antimicrobial combination of two β-lactamase inhibitors for the treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) associated with ...
Wissam K. Kabbara +2 more
doaj +3 more sources
Sulbactam-durlobactam combination therapy for carbapenem-resistant Acinetobacter baumannii sepsis with cutaneous involvement in an infant with acute monocytic leukemia: A case report [PDF]
Frontiers in PharmacologyCarbapenem-resistant Acinetobacter baumannii (CRAb) causes severe infections and poses significant treatment challenges. Sulbactam-durlobactam (SUL-DUR) is a novel antibiotic, but its use in children and infants has not been reported.
Chunxi Fu +12 more
doaj +4 more sources
Cefiderocol and Sulbactam-Durlobactam against Carbapenem-Resistant Acinetobacter baumannii [PDF]
Antibiotics, 2023 Infections caused by carbapenem-resistant Acinetobacter baumannii (CRAB) remain a clinical challenge due to limited treatment options. Recently, cefiderocol, a novel siderophore cephalosporin, and sulbactam-durlobactam, a bactericidal β-lactam–β ...
Arta Karruli +4 more
doaj +3 more sources
Acinetobacter baumannii Resistance to Sulbactam/Durlobactam: A Systematic Review [PDF]
Antibiotics, 2022 Infections caused by carbapenem-resistant Acinetobacter baumannii (CRAB) have limited therapeutic options. Sulbactam-durlobactam is a combination of two βlactamase inhibitors with activity against CRAB under phase 3 clinical investigation. We performed a
Luigi Principe +6 more
doaj +2 more sources
Pharmacokinetic and pharmacodynamic evaluation of sulbactam-durlobactam in a critically ill patient on continuous venovenous hemofiltration infected with carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex. [PDF]
PharmacotherapyAbstract Background Drug databases currently do not provide dosing guidance for sulbactam‐durlobactam in continuous renal replacement therapy. Herein, we present the first in vivo pharmacokinetic (PK) evaluation of sulbactam‐durlobactam during continuous venovenous hemofiltration (CVVH) in a patient with carbapenem‐resistant Acinetobacter baumannii ...
Kufel WD +8 more
europepmc +5 more sources
Frontiers in Cellular and Infection Microbiology, 2022 BackgroundAcinetobacter baumannii is a leading cause of healthcare-associated infections worldwide, due to both its persistence in the hospital setting and ability to acquire high levels of antibiotic resistance. Carbapenem-resistant A.
Dimitra Petropoulou +3 more
doaj +3 more sources
Health Science ReportsPurpose Infections caused by Acinetobacter baumannii, particularly those resistant to antibiotics such as carbapenem, have become a global health crisis with a significant mortality rate.
Ayush Anand +13 more
doaj +2 more sources
Susceptibility toward cefiderocol and sulbactam-durlobactam in extensively drug-resistant Acinetobacter baumannii detected from ICU admission screening in Hanoi, Vietnam, 2023 [PDF]
Microbiology SpectrumInfections due to carbapenem-resistant Acinetobacter baumannii (CRAB) pose significant clinical challenges due to limited treatment options. In this study, we investigated the molecular epidemiology, resistance profiles, and genomic characteristics of ...
Sébastien Boutin +15 more
doaj +2 more sources
Journal of Global Antimicrobial Resistance, 2022 : Objectives: Multidrug-resistant Acinetobacter baumannii (MDR-Ab), particularly strains producing oxacillinase (OXA)-type carbapenemases, have rapidly emerged in health care settings as a frequent cause of serious infections with limited treatment ...
Jacqueline Findlay +3 more
doaj +2 more sources
In Vitro Activity of Sulbactam–Durlobactam against Carbapenem-Resistant Acinetobacter baumannii Clinical Isolates: A Multicentre Report from Italy [PDF]
Antibiotics, 2022 In the present study, the in vitro activity of the sulbactam–durlobactam (SUL–DUR) combination was evaluated against 141 carbapenem-resistant A. baumannii (CRAb) clinical strains collected from six Italian laboratories.
Bernardetta Segatore +17 more
doaj +3 more sources